Compare Cipla with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ABBOTT INDIA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ABBOTT INDIA CIPLA/
ABBOTT INDIA
 
P/E (TTM) x 36.9 47.2 78.2% View Chart
P/BV x 4.3 15.4 27.8% View Chart
Dividend Yield % 0.5 0.4 107.1%  

Financials

 CIPLA   ABBOTT INDIA
EQUITY SHARE DATA
    CIPLA
Mar-20
ABBOTT INDIA
Mar-19
CIPLA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs5868,834 6.6%   
Low Rs3575,458 6.5%   
Sales per share (Unadj.) Rs207.01,731.1 12.0%  
Earnings per share (Unadj.) Rs18.6211.9 8.8%  
Cash flow per share (Unadj.) Rs33.2219.9 15.1%  
Dividends per share (Unadj.) Rs4.0065.00 6.2%  
Dividend yield (eoy) %0.80.9 93.3%  
Book value per share (Unadj.) Rs195.5945.2 20.7%  
Shares outstanding (eoy) m806.3521.25 3,794.6%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.34.1 55.1%   
Avg P/E ratio x25.333.7 75.1%  
P/CF ratio (eoy) x14.232.5 43.7%  
Price / Book Value ratio x2.47.6 31.9%  
Dividend payout %21.530.7 70.1%   
Avg Mkt Cap Rs m379,912151,848 250.2%   
No. of employees `00025.83.5 741.6%   
Total wages/salary Rs m30,2704,356 694.9%   
Avg. sales/employee Rs Th6,459.610,555.5 61.2%   
Avg. wages/employee Rs Th1,171.21,249.9 93.7%   
Avg. net profit/employee Rs Th580.21,292.2 44.9%   
INCOME DATA
Net Sales Rs m166,94936,786 453.8%  
Other income Rs m3,4421,133 303.8%   
Total revenues Rs m170,39137,919 449.4%   
Gross profit Rs m32,0606,047 530.2%  
Depreciation Rs m11,747169 6,942.4%   
Interest Rs m1,97423 8,771.6%   
Profit before tax Rs m21,7826,989 311.7%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3122,485 254.0%   
Profit after tax Rs m14,9954,503 333.0%  
Gross profit margin %19.216.4 116.8%  
Effective tax rate %29.035.6 81.5%   
Net profit margin %9.012.2 73.4%  
BALANCE SHEET DATA
Current assets Rs m117,03827,610 423.9%   
Current liabilities Rs m43,9318,569 512.7%   
Net working cap to sales %43.851.8 84.6%  
Current ratio x2.73.2 82.7%  
Inventory Days Days9660 159.0%  
Debtors Days Days8527 310.5%  
Net fixed assets Rs m107,4241,057 10,164.2%   
Share capital Rs m1,613213 758.8%   
"Free" reserves Rs m156,01819,873 785.1%   
Net worth Rs m157,63020,086 784.8%   
Long term debt Rs m23,6930-   
Total assets Rs m236,62629,409 804.6%  
Interest coverage x12.0311.6 3.9%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.71.3 56.4%   
Return on assets %7.215.4 46.6%  
Return on equity %9.522.4 42.4%  
Return on capital %12.834.9 36.8%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,036369 15,187.6%   
Fx outflow Rs m6,7644,918 137.5%   
Net fx Rs m49,272-4,549 -1,083.0%   
CASH FLOW
From Operations Rs m30,6854,991 614.8%  
From Investments Rs m1,040-2,570 -40.5%  
From Financial Activity Rs m-29,488-1,428 2,065.0%  
Net Cashflow Rs m2,340993 235.6%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 7.9 154.4%  
FIIs % 23.7 0.1 23,700.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.1 153.2%  
Shareholders   161,166 18,270 882.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens above 50,000-Mark; Tata Motors & Bajaj Finance Top Gainers(09:30 am)

Asian share markets rose for the third straight session today, tracking gains in US peers. The Nikkei is trading up by 0.7% and the Hang Seng is trading up by 0.1%.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 21, 2021 10:02 AM

TRACK CIPLA

CIPLA - UNICHEM LAB COMPARISON

COMPARE CIPLA WITH

MARKET STATS